

Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell

Yanran He, Karin Schreiber, Steven P. Wolf, Frank Wen, Catharina Steentoft, Jonathan Zerweck, Madeline Steiner, Preeti Sharma, H. Michael Shepard, Avery Posey, Carl H. June, Ulla Mandel, Henrik Clausen, Matthias Leisegang, Stephen C. Meredith, David M. Kranz, Hans Schreiber

JCI Insight. 2019;4(23):e135306. <https://doi.org/10.1172/jci.insight.135306>.

Corrigendum

Original citation: *JCI Insight*. 2019;4(21):e130416. <https://doi.org/10.1172/jci.insight.130416> Citation for this corrigendum: *JCI Insight*. 2019;4(23):e135306. <https://doi.org/10.1172/jci.insight.135306> The authors' conflict-of-interest statement was not included in the manuscript. The HTML and PDF versions have been updated to include this information. The correct statement is also below. Conflict of interest: HS and YH are inventors of intellectual property (IP) surrounding 237Ab-derived CARs. DMK has ownership interest in Bellicum Pharmaceuticals, Agenus Inc., and Jounce Therapeutics and is a consultant/advisory board member for AbbVie. DMK and PS are coinventors of the IP surrounding 237Ab-derived CARs. CHJ reports research funding from Novartis, and he is a scientific founder of Tmunity Therapeutics, for which he has founder's stock but no income. CHJ also works under a research collaboration involving the University of Pennsylvania and the Novartis Institutes of Biomedical Research, Inc, and he is an inventor of IP licensed by the University of Pennsylvania to Novartis. ADP reports research funding from Tmunity Therapeutics around the clinical development of 5E5-CART cells and has IP licensed to Novartis for CART cell therapy as well as gene therapy. HC, CS, and UM are coinventors of IP surrounding 5E5Ab-derived CARs licensed by the University of Copenhagen to Novartis. The authors regret the error.

Find the latest version:

<https://jci.me/135306/pdf>



Corrigendum

Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell

Yanran He, Karin Schreiber, Steven P. Wolf, Frank Wen, Catharina Steentoft, Jonathan Zerweck, Madeline Steiner, Preeti Sharma, H. Michael Shepard, Avery Posey, Carl H. June, Ulla Mandel, Henrik Clausen, Matthias Leisegang, Stephen C. Meredith, David M. Kranz, and Hans Schreiber

Original citation: *JCI Insight*. 2019;4(21):e130416. <https://doi.org/10.1172/jci.insight.130416>.

Citation for this corrigendum: *JCI Insight*. 2019;4(23):e135306. <https://doi.org/10.1172/jci.insight.135306>.

The authors' conflict-of-interest statement was not included in the manuscript. The HTML and PDF versions have been updated to include this information. The correct statement is also below.

Conflict of interest: HS and YH are inventors of intellectual property (IP) surrounding 237Ab-derived CARs. DMK has ownership interest in Bellicum Pharmaceuticals, Agenesis Inc., and Jounce Therapeutics and is a consultant/advisory board member for AbbVie. DMK and PS are coinventors of the IP surrounding 237Ab-derived CARs. CHJ reports research funding from Novartis, and he is a scientific founder of Tmunity Therapeutics, for which he has founder's stock but no income. CHJ also works under a research collaboration involving the University of Pennsylvania and the Novartis Institutes of Biomedical Research, Inc, and he is an inventor of IP licensed by the University of Pennsylvania to Novartis. ADP reports research funding from Tmunity Therapeutics around the clinical development of 5E5-CART cells and has IP licensed to Novartis for CART cell therapy as well as gene therapy. HC, CS, and UM are coinventors of IP surrounding 5E5Ab-derived CARs licensed by the University of Copenhagen to Novartis.

The authors regret the error.